PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) Clinical and Non-Clinical Studies, Key Companies, Therapeutic Assessment, Emerging Therapies, Treatment Algorithm, and Pipeline Analysis | Arcus Biosciences, Akeso Biopharma, Biotheus, GlaxoSmithKline, AstraZe

PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) Pipeline constitutes 25+ key companies continuously working towards developing 30+ PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) treatment therapies, analyzes DelveInsight.

PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) Overview:

Lung cancer remains one of the leading causes of cancer-related deaths worldwide, with a poor prognosis. However, the introduction of immune checkpoint inhibitors targeting programmed death-1 (PD-1) and programmed death-ligand 1 (PD-L1) has significantly transformed the treatment landscape for patients with non-small cell lung cancer (NSCLC). Blocking the PD-1 receptor and its ligand PD-L1 has demonstrated strong therapeutic responses and improved survival rates in both preclinical and clinical studies for patients with locally advanced or metastatic NSCLC.

PD-1 is a Type I transmembrane protein expressed on T cells, B cells, natural killer cells, activated monocytes, and dendritic cells (DCs). Its two ligands, PD-L1 and PD-L2, are also Type I transmembrane proteins but differ in their expression patterns. PD-L1 can be found on T cells, B cells, DCs, macrophages, various nonhematopoietic cells, and tumor cells. PD-1 and its ligands consist of a signal sequence, an immunoglobulin (Ig) domain, transmembrane domains, and a short cytoplasmic tail.

Upon binding to PD-L1 or PD-L2, PD-1 undergoes phosphorylation at two intracellular tyrosine sites. This leads to the recruitment of phosphatases SHP-1 and SHP-2, which interact with the ITIM and ITSM motifs of PD-1, ultimately suppressing antigen receptor signaling. The interaction between PD-1 and its ligands inhibits effector T-cell function, whereas the engagement of B7-1/B7-2 with CD28 promotes T-cell proliferation.

Request for a detailed insights report on PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) pipeline insights @ https://www.delveinsight.com/report-store/pd-1-non-small-cell-lung-cancer-pd-1-nsclc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

"PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) Pipeline Insight 2025" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) Therapeutics Market.

Key Takeaways from the PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) Pipeline Report

DelveInsight's PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) pipeline report depicts a robust space with 25+ active players working to develop 30+ pipeline therapies for PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) treatment.
Key PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) companies such as Arcus Biosciences, Akeso Biopharma, Biotheus, GlaxoSmithKline, AstraZeneca, Pfizer, Shandong Boan Biotechnology, Genor Biopharma, and others are evaluating new drugs for PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) to improve the treatment landscape.
Promising PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) pipeline therapies in various stages of development include Zimberelimab, PM8002, RPH075, and others.

Recent breakthroughs in the PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) Pipeline Segment:

In August 2025, the FDA approved AstraZeneca's durvalumab for the treatment of adult patients with NSCLC after surgery, expanding its use beyond late-stage cases where surgery is not an option.
In January 2023, the FDA approved pembrolizumab as an adjuvant treatment following resection and platinum-based chemotherapy for patients with stage IB (T2a ≥4 cm), II, or IIIA NSCLC.

PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) Pipeline Analysis
The report provides insights into:
The report provides detailed insights into the key companies that are developing therapies in the PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) Market.
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) treatment.
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) market.

Download our free sample page report on PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) pipeline insights @ https://www.delveinsight.com/sample-request/pd-1-non-small-cell-lung-cancer-pd-1-nsclc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) Emerging Drugs

Zimberelimab: Arcus Biosciences
PM8002: Biotheus
RPH075: R-Pharm

PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) Companies

Around 25 or more key companies are actively developing therapies for PD-1-positive Non-Small Cell Lung Cancer (PD-1+ NSCLC). Among them, companies with drug candidates in the most advanced stage of development, specifically Phase III, include Arcus Biosciences.

DelveInsight's report covers around 30+ products under different phases of clinical development like

Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates

PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Intravenous
Subcutaneous
Oral
Intramuscular

PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) Products have been categorized under various Molecule types such as

Monoclonal antibody
Small molecule
Peptide

Download Sample Pages to Get an in-depth Assessment of the Emerging PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) Therapies and Key Companies: PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) Clinical Trials and advancements @ https://www.delveinsight.com/report-store/pd-1-non-small-cell-lung-cancer-pd-1-nsclc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) Pipeline Therapeutic Assessment
• PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) Assessment by Product Type
• PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) By Stage
• PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) Assessment by Route of Administration
• PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) Assessment by Molecule Type

Download PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) Sample report to know in detail about the PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) treatment market @ PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) Therapeutic Assessment @ https://www.delveinsight.com/sample-request/pd-1-non-small-cell-lung-cancer-pd-1-nsclc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Table of Content

1. Report Introduction
2. Executive Summary
3. PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) Current Treatment Patterns
4. PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) Late-Stage Products (Phase-III)
7. PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) Discontinued Products
13. PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) Product Profiles
14. PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) Key Companies
15. PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) Key Products
16. Dormant and Discontinued Products
17. PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) Unmet Needs
18. PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) Future Perspectives
19. PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) Analyst Review
20. Appendix
21. Report Methodology

Request the Sample PDF to Get Detailed Insights About the PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) Pipeline Reports Offerings: https://www.delveinsight.com/report-store/pd-1-non-small-cell-lung-cancer-pd-1-nsclc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Contact Info:
Kritika Rehani
krehani@delveinsight.com
info@delveinsight.com
+14699457679

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.